GoldVariants, a resource for sharing rare genetic variants detected in bleeding, thrombotic, and platelet disorders: Communication from the ISTH SSC Subcommittee on Genomics in Thrombosis and Hemostasis. by Megy, Karyn et al.
J Thromb Haemost. 2021;00:1–6.   | 1wileyonlinelibrary.com/journal/jth
Received: 5 May 2021  | Accepted: 9 July 2021
DOI: 10.1111/jth.15459  
R E C O M M E N D A T I O N S  A N D  G U I D E L I N E S
GoldVariants, a resource for sharing rare genetic variants 
detected in bleeding, thrombotic, and platelet disorders: 
Communication from the ISTH SSC Subcommittee on 
Genomics in Thrombosis and Hemostasis
Karyn Megy1,2 |   Kate Downes1,2,3 |   Marie- Christine Morel- Kopp4,5 |   José M. Bastida6  |   
Shannon Brooks7 |   Loredana Bury8 |   Eva Leinoe9  |   Keith Gomez10  |   Neil V. Morgan11  | 
Maha Othman12,13  |   Willem H. Ouwehand1,2,3 |   Juliana Perez Botero14 |   José Rivera15 |   
Harald Schulze16  |   David-  Alexandre Trégouët17 |   Kathleen Freson18
1Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK
2NIHR BioResource, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge, UK
3East Genomic Laboratory Hub, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
4Department of Haematology and Transfusion Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia
5Northern Blood Research Centre, Kolling Institute, The University of Sydney, Sydney, New South Wales, Australia
6Department of Hematology, IBSAL- Hospital Universitario de Salamanca, Salamanca, Spain
7International Society on Thrombosis and Haemostasis (ISTH), Carrboro, North Carolina, USA
8Section of Internal and Cardiovascular Medicine, Department of Medicine, University of Perugia, Perugia, Italy
9Department of Haematology, Rigshospitalet, National University Hospital, Copenhagen, Denmark
10Haemophilia Centre and Thrombosis Unit, Royal Free London NHS Foundation Trust, London, UK
11Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
12Biomedical and Molecular Sciences School of Medicine Queen’s University, Kingston, Ontario,, Canada
13School of Baccalaureate Nursing, St. Lawrence College, Kingston, Ontario, Canada
14Division of Hematology/Oncology, Medical College of Wisconsin and Versiti Diagnostic Laboratories, Milwaukee, Wisconsin, USA
15Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB- 
Arrixaca, CIBERER- U765, Murcia, Spain
16Institute of Experimental Biomedicine, University Hospital Wuerzburg, Wuerzburg, Germany
17INSERM UMR_S 1219, Bordeaux Population Health Research Center, University of Bordeaux, Bordeaux, France
18Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium
Manuscript handled by: Joost Meijers 
Final decision: Joost Meijers, 09 July 2021 
Correspondence
Kathleen Freson, Department of 
Cardiovascular Sciences, Center for 
Molecular and Vascular Biology, KU 




The implementation of high- throughput sequencing (HTS) technologies in research 
and diagnostic laboratories has linked many new genes to rare bleeding, thrombotic, 
and platelet disorders (BTPD), and revealed multiple genetic variants linked to those 
disorders, many of them being of uncertain pathogenicity when considering the ac-
cepted evidence (variant consequence, frequency in control datasets, number of 
This is an open access article under the terms of the Creative Commons Attribution- NonCommercial License, which permits use, distribution and reproduction 
in any medium, provided the original work is properly cited and is not used for commercial purposes.
© 2021 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis.
2  |    MEGY Et al.
1  |  INTRODUC TION
High- throughput sequencing (HTS) technologies have entered the 
field of bleeding, thrombotic, and platelet disorders (BTPD)1– 4 and, 
following guidelines for sequence variant interpretation, clinical lab-
oratories perform genetic testing for diagnostics and improved clini-
cal management. Accurate genetic diagnosis of BTPD is essential for 
differential diagnosis; for guiding treatment in the case of disorders 
sharing the same laboratory platelet phenotype, such as platelet- type 
von Willebrand disease and von Willebrand disease type 2B;5 or for 
determining prognosis and informing patient management when a 
phenotype- - genotype correlation exists, such as in Hermansky- Pudlak 
syndrome6 or MYH9- related disorders.7 The identification of a genetic 
variant might have a strong impact on a patient’s life, for example when 
a variant is found in RUNX1, ETV6, or ANKRD26 genes associated with 
increased leukemic risk, and may represent an unsolicited finding.8
An important first step in setting up an accredited diagnostic 
HTS panel test for BTPD is to define the set of diagnostic- grade 
(or TIER1) genes; this task was taken up by the Scientific and 
Standardization Committee (SSC) for Genetics in Thrombosis and 
Haemostasis (GinTH), which resulted in an initial list of 91 genes.9 
This list is re- assessed by the SSC- GinTH at the yearly International 
Society on Thrombosis and Haemostasis (ISTH) meeting and cur-
rently contains 93 TIER1 genes (www.isth.org/page/GinTh_GeneL 
ists). This webpage also contains a list of TIER2 genes that currently 
lack sufficient evidence to be considered proven diagnostic- grade 
genes, mostly because they were typically discovered in single or 
small pedigrees and still require confirmation studies in independent 
pedigrees and functional assays or a mouse model.
The implementation of HTS testing for BTPD diagnostics has 
led to an explosion of genetic information, which required im-
proved variant curation and data sharing. The American College 
of Medical Genetics and Genomics/Association for Molecular 
Pathology (ACMG/AMP) guidelines proposed a variant classifi-
cation system using five levels: benign, likely benign, variant of 
uncertain significance (VUS), likely pathogenic, and pathogenic. 
Variants in the pathogenic and likely pathogenic categories have 
clinical significance and VUS might subsequently develop clinical 
significance if they become re- classified into one of these cate-
gories.10 Data sharing of genotype and phenotype information is 
essential to provide curated evidence for genetic variants, espe-
cially for VUS, which cannot be conclusively assigned to either a 
benign or pathologic category on the basis of information often 
obtained from a case report. Although several gene- specific vari-
ant databases have arisen over time for BTPD, such as those from 
the European Association for Haemophilia and Allied Disorders 
(EAHAD) for F5, F7, F8, F9, F10 and VWF deficiencies (https://dbs.
eahad.org) and the Glanzmann Thrombasthenia Database (https://
glanz mann.mcw.edu), such databases do not exist for most BTPD 
genes. In contrast, variant information for all genes is available 
from the commercial Human Gene Mutation Database (HGMD), al-
though this database doesn’t use the ACMG/AMP criteria for vari-
ant classification and is populated with false- positive pathogenic 
variants.2 The free- access version of HGMD database does not 
include variants published in the last 3 years. Since 2013, the open- 
access ClinVar (Clinically Relevant Variations) archival database ag-
gregates information about genomic variation and the relationship 
to human disease. However, ClinVar contains numerous variants 
that have been submitted by separate labs applying the variant 
classification criteria differently, resulting in heterogeneous patho-
genicity assignments, some being classified as both benign and 
pathogenic. It is the task of the ClinGen Variant Curation Expert 
Panels to define gene- specific modification to the general ACMG/
AMP variant curation rules and re- evaluate ClinVar variants based 
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reported patients, prediction models, and functional assays). The sequencing effort 
has also resulted in resources for gathering disease- causing variants associated with 
specific genes, but for BTPD, such well- curated databases exist only for a few genes. 
On the other hand, submissions by individuals or diagnostic laboratories to the variant 
database ClinVar are hampered by the lack of a submission process tailored to capture 
the specific features of hemostatic diseases. As we move toward the implementation 
of HTS in the diagnosis of BTPD, the Scientific and Standardization Committee for 
Genetics in Thrombosis and Haemostasis has developed and tested a REDCap- based 
interface, aimed at the community, to submit curated genetic variants for diagnostic- 
grade BTPD genes. Here, we describe the use of the interface and the initial submis-
sion of 821 variants from 30 different centers covering 14 countries. This open- access 
variant resource will be shared with the community to improve variant classification 
and regular bulk data transfer to ClinVar.
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on the modified rules, as currently done for ITGA2B and ITGB3 vari-
ants causing Glanzmann thrombasthenia.11 ClinGen is a National 
Institutes of Health (NIH)- funded research consortium that aims 
to build a central resource that defines the clinical relevance of 
genes and variants for use in clinical diagnostics. The ClinGen clin-
ical domain working group for hemostasis and thrombosis (https://
clini calge nome.org/worki ng- group s/clini cal- domai n/hemos tasis 
- throm bosis/) will oversee gene and variant curation activities for 
BTPD. Because these curation processes are expected to take sev-
eral years for all BTPD genes, it is critical in the meantime to capture 
all variants identified by HTS activities in our community. Variant 
data sharing is recognized as a real necessity, especially for rare 
disorders; however, clinical laboratories might not have the time or 
interest to deposit their rare causal variants to public repositories. 
The submission of variants to the ClinVar database is laborious and 
many clinical laboratories using HTS do not submit identified vari-
ants. In addition, for established gene- disease associations, causal 
variants identified in patients are not routinely published, and with-
out submission to a public database, this information, essential for 
evidence- based variant interpretation, is not available for clinical 
diagnostics. Finally, some general laboratories lack the appropriate 
knowledge in BPTD and submit variants to ClinVar without suffi-
cient or even no phenotype information.
To aid variant sharing, the SSC- GinTH has developed 
“GoldVariants,” an open- access and user- friendly tool to capture 
variants. It has a REDCap- based interface and has been designed 
for a rapid and easy submission of BTPD variants, which will then be 
deposited in ClinVar half- yearly. Here we describe the development 
and testing of GoldVariants by 30 expert centers, resulting in the 
deposition of 821 variants in ClinVar.
2  |  METHODS
2.1  |  GoldVariants project and resource
The ISTH GoldVariants project was an initiative of the SSC GinTH and 
was supported by other SSCs (Table S1 in supporting information). 
One aim in this project was the development of the GoldVariants 
resource. Experts with publications related to HTS for diagnostics of 
BTPDs were contacted and the responders are the centers involved 
in this study. These experts participated in at least one of the two 
SSC- GinTH workshops (ISTH 2019 or virtual workshop in September 
2020) organized to develop and test the GoldVariants resource. The 
resource, built around REDCap, is maintained by ISTH and will be 
open access for the scientific community. Transfer to ClinVar will be 
coordinated by GinTH.
2.2  |  GoldVariants workflow
The GoldVariants resource is an intermediate platform for the depo-
sition of genetic variants to ClinVar. The workflow is presented in 
Figure S1 in supporting information. Briefly, variants are submitted 
by the community and aggregated in a single file. Twice a year the 
file is “frozen,” versioned, and deposited in ClinVar and on the ISTH 
website.
3  |  RESULTS
3.1  |  The ISTH GoldVariants resource: A REDCap– 
based interface to submit rare variants for BTPD
The aim was to deliver an ISTH community- based REDCap solu-
tion for the safe sharing of genotype and phenotype data among 
clinicians, scientists, and the public to support international 
collaboration and improve variant classification for BTPD. The 
GoldVariants submission interface can be accessed via https://
is.gd/GinTH_Varia ntCap ture (or indirectly via the TIER1 gene 
list webpage www.isth.org/page/GinTh_GeneL ists). Genetic 
variants can be submitted in two ways: (1) uploading a single 
variant via the interface by filling in a form, or (2) uploading a 
batch of variants by completing a worksheet (containing exam-
ples) that can be submitted via email. Table 1 provides an over-
view of the mandatory and optional information requested in 
the five sections: submitter, gene, variant, clinical significance, 
and phenotype- related patient information. These fields are 
in line with the requirements for variant deposition in ClinVar. 
The only compulsory information regarding the phenotype is 
the “disorder name,” while other clinical or laboratory data can 
be entered under the optional box “clinical features.” As stated 
above, sufficient phenotype information is critical for variant 
interpretation.
3.2  |  GoldVariants test phase with the 
submission of 821 genetic variants
So far, 821 (611 unique) variants have been submitted to the 
GoldVariants resource since it opened after July 2020. Submissions 
originate from 30 different expert centers in 14 countries across the 
world (North and South America, Europe, Asia and Oceania; Table 
S2 in supporting information). Submissions ranged from a single 
variant, via the online portal, to 249 variants, via the batch upload. 
The majority of the variants were single nucleotide variants or small 
insertion- deletions (indels), with the remaining variants submitted 
being large deletions (Figure 1A). A total of 18 deletions have been 
submitted in 12 different genes with 3 deletions in both VWF and 
RUNX1 as most common. These ranged from single exon deletions 
to large deletions encompassing multiple genes that are relatively 
simple to detect using HTS data, compared to complex structural 
variants or those not detectable using HTS methods (e.g., F8 intron 
1 and 22 inversions).1 Out of the 821 variants, 81 were identified 
as homozygous; 32 as hemizygous; and 702 were heterozygous, of 
which 57 were in compound heterozygosity.
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The majority of the 611 unique variants have been classified by 
the submitter as pathogenic (23%), likely pathogenic (36%), or VUS 
(39.5%), while 1.5% have been defined as risk factors or benign 
(Figure 1B, insert). Only 6 variants were submitted as likely benign 
and benign. We especially encourage the submission of variants 
listed in ClinVar as VUS or (likely) pathogenic where additional ev-
idence obtained through co- segregation or functional studies sug-
gests reclassification as (likely) benign. Variants were detected in 68 
out of the 93 diagnostic- grade genes (Version ISTH2020.1,9), with 
the number of variants per gene varying from nearly 60 for VWF to a 
single variant detected in 14 different genes (Figure 1B).
3.3  |  Variant classification differences
A total of 17 single nucleotide variants (SNV) in 10 genes were sub-
mitted by more than one center and with different pathogenicity 
scores, illustrating the difficulty of the variant classification process 
even when using the same ACMG/AMP criteria (Table S3 in support-
ing information). This is also visible in the “ClinVar Interpretation” 
column of the table, providing the different pathogenicities for those 
variants in ClinVar. In addition, four SNVs (ANKRD26 c.- 126T>C, 
ITGA2B R1026W, PROS1 S501P, and VWF Y1584C) submitted by 
the same center received different classification scores reflect-
ing the evolution of interpretation as evidence for pathogenicity 
accumulates over time (usually based on the occurrence of the same 
variant in unrelated patients with similar phenotypes or familial 
co- segregation studies). Although the aim of this project is not to 
reclassify submitted variants, Table S3 shows the comparison with 
the current ClinVar variant interpretation and, if available, the infor-
mation obtained from gene- specific databases. By submitting these 
variants to ClinVar, ClinGen variant curators can classify these vari-
ants with similar scores. If more unrelated patients carry the same 
variant and share phenotypes, a VUS variant can become clinically 
significant. Providing sufficient clinical and laboratory phenotype in-
formation associated with each VUS variant is important for variant 
reclassification processes. Variant deposition into ClinVar through 
the GoldVariants resource will aid this curation work.
3.4  |  Accessing submitted variants and 
future updates
Variants will be deposited in ClinVar, but with indication of the 
submitter and their laboratory, as well as any associated publica-
tion describing the patients. This will help patient tracking in order 
to mitigate patients being represented more than once within the 
ClinVar database. Deposition will be performed twice a year, under 
the name “ISTH- SSC Genomics in Thrombosis and Hemostasis” 
(Table S2). GoldVariants will also be accessible as a downloadable 
TA B L E  1  Information required for the variant submission interface
Items Mandatory information Optional information
1. Submitter • Name of center
• Email address
• Name of submitter
2. Gene • Gene name (automatically coupled to disorder 
name, for some genes more than single disorder 
name is possible)
• Reference transcript (RefSeq_only)
• Second transcript (if relevant)
3. Variant Single nucleotide variant/indel
• Transcript position (HGVSc) eg. c.2104C>T
• Protein position (HGVSp) eg. p.Arg702Cys
• Zygosity
Structural variant
• Type (deletion, insertion, inversion, complex)
• Chromosome
• Genomic position start (bp)
• Genomic position end (bp)
• GenomeBuild
• Zygosity
4. Clinical significance • Pathogenicity (pathogenic, likely pathogenic, 
VUS, likely benign, benign, risk factor)
• ACMG/AMP criteria followed (Yes or No)
• If Yes (ACMG/AMP): which ACMG/AMP rules were used
• If No (ACMG/AMP): what other criteria were used
• PubMed ref if variant has been published
5. Patient information • Affected status
• Disorder name
• Allelic origin
• Clinical or research sample
• Platform type
• Sex
• Age at diagnosis
• Ethnicity
• Family history
• Description of phenotype
Abbreviations: ACMG, American College of Medical Genetics and Genomics; AMP, Association for Molecular Pathology; VUS, variant of uncertain 
significance.
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file from the TIER1 gene list ISTH webpage (www.isth.org/page/
GinTh_GeneL ists), which will also be updated twice a year.
4  |  DISCUSSION
The ISTH GoldVariants resource currently contains a total of 821 vari-
ants submitted by 30 different expert centers, using different gene 
screening methods for diagnosis of patients with BTPD. GoldVariants 
is now open for all submissions from the community and aims to de-
posit variants to ClinVar twice a year (July/December). Each submis-
sion center is responsible for the variant information and no additional 
variant curation steps will be performed after the initial variant sub-
mission to the GoldVariants resource or before their deposition to 
ClinVar. Each variant carries a link to the initial submitter to allow for 
contact in case additional information about that particular variant is 
required. One shortcoming of all current variant databases is the fact 
that, to preserve patient anonymity, no unique patient identifiers are 
assigned.
It remains important to submit variants that are already present 
in ClinVar or the GoldVariants resource if identified in another pa-
tient (or family). Multiple submissions of the same variant in different 
families with similar laboratory or clinical phenotypes will allow VUS 
variant reclassification to (likely) pathogenic where segregation with 
a specific trait is observed or (likely) benign when lack of segregation 
is demonstrated. The GoldVariants resource will be freely accessible 
for the community via the ISTH website (Figure 1). This resource will 
facilitate future variant curation work. Though ClinGen is not part of 
this project, the GoldVariants submission to ClinVar can support the 
variant curation work undertaken by the different ClinGen working 
groups for coagulation, platelet, and thrombotic disorders. To try and 
understand why the same variant identified in patients with similar 
phenotypes have different pathogenicity classifications by different 
laboratories, we will ask submitters to list which ACMG/AMP criteria 
were used; however, this is not mandatory for submission. A total of 
56 variants (29 variants in 11 platelet genes and 27 variants in 10 
coagulation genes) were submitted from at least two unrelated index 
patients, and such information allows for variant reclassification; this 
is of prime importance especially for VUS, to improve curation and 
appropriate counseling of patients with such variants in the future.
The next effort from this SSC- GinTH initiative should be to 
capture variants in TIER2 genes that currently lack evidence to be 
considered as proven diagnostic- grade.9 Genotype- - phenotype in-
formation related to variants in these genes is one way to upgrade 
these genes to TIER1 status. Other support can come from spe-
cific functional assays or cellular and animal models. Variant cura-
tion is not only assisted by information available from pathogenic 
databases but also from knowledge about their population allele 
frequency.2 The population size in databases that provide such in-
formation is also rapidly growing with the largest and most widely 
used database of variant allele frequency being gnomAD (V2 dataset 
in GRCh37 includes 125,748 exomes and 15,708 genomes and V3.1 
dataset in GRCh38 includes 76,156 genomes).12 The UK Biobank has 
released 200,000 exomes in October 2020 (interim analysis of these 
data in Van Hout et al.13) and is expected to release variant informa-
tion from 200,000 genomes by the end of 2021. In contrast to the 
gnomAD database, some phenotypic information about participants 
in the UK Biobank study will be available. These expanding popula-
tion datasets will also significantly improve variant classification for 
rare diseases.
F I G U R E  1  Summary of the variant types, pathogenicity, and genes. A, Proportion of unique variants per type single nucleotide variants 
(SNVs)/indels or structural variants (SVs). B, Number of unique variants, per gene and per pathogenicity and (insert) proportion of unique 
variants that are benign/likely benign/risk factor, variant of uncertain significance, likely pathogenic, or pathogenic
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